Diabetes
Refine Search
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
US drug developer Reata Pharmaceuticals has entered into a licensing agreement that provides Japan's Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata's lead compound, bardoxolone methyl, in Japan and other selected Asian markets. Under the terms of the deal, Reata is eligible to receive up to $272 million in up-front fees and milestone payments, in addition to double-digit royalties. 8 January 2010
Pharmaceutical
US firm Incyte saw its shares rise 5% to $8.92 after announcing it had entered into an exclusive worldwide license and collaboration deal with drug major Eli Lilly for the development and commercialization of its oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis. 22 December 2009
Pharmaceutical
Swiss drug major Roche has announced headline results from the fourth and fifth of eight T-emerge Phase III studies involved taspoglutide, a diabetes drug candidate licensed from France's Ipsen, with both studies meeting their primary endpoints. 18 December 2009
Pharmaceutical
A batch of drug licensing deals were announced yesterday and today between pharmaceutical majors and with biotechs, including developmental and already marketed products. 15 December 2009
Pharmaceutical
Following marketing approval by the European Commission and the subsequent UK launch on July 7, 2009 of Novo Nordisk's Victoza (liraglutide), the first once-daily human glucagon-like peptide-1 (GLP-1) analog which regulates blood sugar in a glucose-dependent manner, the Scottish Medicines Consortium (SMC) has announced its advice to the National Health Service Boards and Area Drug and Therapeutic Committees (ADTCs) supporting its use for people with type 2 diabetes in NHS Scotland. 9 December 2009
Pharmaceutical
The type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013, according to a news report from research and advisory firm Decision Resources. The projected 15 percent annual growth rate is attributed to a growing prevalent and drug-treated population, increased use of new generation antidiabetics such as Merck's Januvia (sitagliptin), Novartis's Galvus (vildagliptin), Sanofi-Aventis's Lantus (insulin glargine [rDNA origin] Injection), and Novo Nordisk's Levemir (insulin detemir), and the launch of several novel agents like Amylin/Eli Lilly/Alkermes' Byetta LAR (exenatide). 7 December 2009
Pharmaceutical
Results from two further Phase III clinical trials show that Swiss pharmaceutical major Roche's diabetes drug candidate, once-weekly taspoglutide, met its primary end-points in head-to-head study with US drug giant Merck & Co's Januvia (sitagliptin) ' which generated global sales of some $1.4 billion in 2008 - and placebo. 4 December 2009
Pharmaceutical
Drug major Sanofi-Aventis was in the news on two fronts: it has received final approval to market its arrhythmia drug Multaq (dronedarone) in the European Union and has signed a memorandum of understanding with Prominvest, a wholly-owned subsidiary of the Russian state corporation Rostekhnologii, confirming its intent to participate in the 'Pharmpolis Project' using the French company's new modern insulin factory located in Russia as a pilot initiative. 30 November 2009
Pharmaceutical
A new survey of patients with type 2 diabetes shows that more than three-quarters of them are taking medication to control their diabetes. Of this group, 84% would consider switching medication if it meant taking fewer tablets. Yet nearly half had never had any changes made to their medication, even though 35% had been diagnosed with type 2 diabetes for between five and 10 years, and 13% for more than 10 years. 18 November 2009
Pharmaceutical
As the USA marks American Diabetes Month, Health and Human Services Secretary Kathleen Sebelius released a new report, Preventing and Treating Diabetes: Health Insurance Reform and Diabetes in America. 12 November 2009
Pharmaceutical
The US Food and Drug Administration yesterday acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat type 2 diabetes marketed by Eli Lilly and manufactured by Amylin. 3 November 2009
Pharmaceutical
The world's largest maker of insulin, Denmark's Novo Nordisk, says that third-quarter profit rose 3% to 2.8 billion Danish kroner ($555 million) compared with the prior-year Chief executive Lars Rebien Sorensen noted that robust sales growth of the company's portfolio of modern insulins was the key driver. 2 November 2009
Pharmaceutical
French specialty pharmaceutical group says that its drug Dysport (abobotulinumtoxinA for Injection) is now available in the USA for the treatment of cervical dystonia in adults and announced positive findings with its diabetes drug taspoglutide. 29 October 2009
Pharmaceutical
US drugmakers Ligand Pharmaceuticals and Metabasis Therapeutics have entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of the latter. 27 October 2009
Pharmaceutical
Participants in a double-blind, placebo-controlled 20-week trial with Danish drugmaker Novo Nordisk's diabetes drug Victoza (liraglutide) lost significantly more weight than did those on placebo (p=0.003 for liraglutide 1.2mg and p<0.0001 for liraglutide 1.8-3.0mg) and Swiss drug major Roche's Xenical (orlistat [p=0.003 for liraglutide 2.4mg and p<0.0001 for liraglutide 3.0mg]), according to a study published in the prestigious medical journal The Lancet. 26 October 2009
Pharmaceutical
In another move to expand its pipeline, French drug major Sanofi-Aventis has reached agreement with USA-based Wellstat Therapeutics for a global license to develop, manufacture and commercialize PN2034, a first-in-class oral insulin sensitizer for the treatment of type 2 diabetes. PN2034 was discovered by Wellstat and is currently in Phase II clinical trials to reverse insulin resistance in the liver of diabetic patients. 21 October 2009
Pharmaceutical
A staggering 285 million people worldwide have diabetes, according to new data released by the International Diabetes Federation (IDF). The latest figures from the IDF Diabetes Atlas indicate that people in low and middle-income countries (LMCs) are bearing the brunt of the epidemic, and that the disease is affecting far more people of working age than previously believed. 21 October 2009
Pharmaceutical
Belgian firm Galapagos has expanded its global strategic alliance in metabolic diseases with an affiliate of US drug major Merck & Co. to incorporate the development of new therapies for atherosclerosis, which will generate total alliance milestones of more than double to over 400 million euros ($590.4 million), plus royalties on worldwide sales. 15 October 2009
Biotechnology
Biosimilar insulins and insulin analogs stand to erode $6.1 billion in brand sales in the USA and Europe (France, Germany, Italy, Spain and the UK) by 2018, saving health care systems $3.8 billion in the process, according to a new report from research and advisory firm Decision Resources. 'Biosimilars' are copies of original drugs generated through bioengineering but, unlike the typical generic, are not deemed to be completely bioequivalent. 15 October 2009
Pharmaceutical
Recently-approved for marketing in the treatment of type 2 diabetes in the USA, Bristol-Myers Squibb/AstraZeneca's Onglyza (saxagliptin) is covered by 44% of commercial health plans but less than one percent of Medicare plans. According to the Formulary Forum report entitled Formulary Advantages in Type 2 Diabetes: Impact of Current and Future DPP-IV Inhibitors and GLP-1 Analogues on Advantaged Reimbursement Status for Key Brands, among plans that have Onglyza on formulary, the majority have placed the drug on Tier 3 14 October 2009
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze